Carl P. Weiner, M.D., M.B.A., FACOG
Associate Director, Institute for Reproductive Health and Regenerative Medicine
Director, Center for Developmental Origins of Health and Adult Disease
Center for Minimally Invasive and Robotic Surgery Center for Advanced Fetal Care
Publications: Click here
Dr. Carl Philip Weiner is a professor of obstetrics and gynecology and professor of integrative and molecular physiology at the University of Kansas School of Medicine, and professor of pharmaceutical sciences at the University of Kansas School of Pharmacy. He is the associate director of the Institute for Reproductive Health and Regenerative Medicine and leads the Center for the Developmental Origins of Health and Disease. Dr. Weiner has spent his career in academic medicine and is dedicated to teaching, research and clinical service. His prior administrative responsibilities included chair, division director, fellowship director and residency director. His team received one of nine U.S. Public Health Service designations as a National Center of Excellence for Women's Health Care. He created several successful Centers for Advanced Fetal Care, most recently in Kansas City, Kansas.
Born in Fair Lawn, New Jersey, Dr. Weiner received his B.A. from Lehigh University in 1972, his M.D. from the Medical College of Georgia in 1977, and his masters in business administration from Loyola College in 2002.
On the completion of his clinical training, Dr. Weiner joined the faculty at the University of Iowa College of Medicine where he rose to the rank of professor with tenure within seven years. In 1984, he began one of the first multi-disciplinary fetal diagnosis and treatment units in the country. He left the University of Iowa in 1996 for the chair position at Maryland. He left Maryland in 2006 to direct women's services at KU Medical Center and create an institute for drug development that targets pregnancy.
Dr. Weiner has received awards for both teaching and research. He has more than 200 peer-reviewed publications and edits five textbooks, including international best sellers such as "High Risk Pregnancy: Management Options," now in its 4th edition, and "Drugs for Pregnant and Lactating Women" now in its 2nd edition. He has been continuously funded from extramural sources since 1983, receiving more than 35 awards. He serves as a regular reviewer for two NIH Study Sections, and has been a member of the CIHR Clinical Investigation Grants Committee. Dr. Weiner's laboratory was the first to demonstrate sex hormone regulation of the nitric oxide enzyme system. Presently, his investigative interests focus on the regulation of uterine quiescence during pregnancy, impact of chronic fetal hypoxia, and the discovery, interpretation and application of biomarkers for reproductive pathology. His laboratory has multiple firsts in the application of proteomics, genomics and transcriptomics to reproductive science. Dr. Weiner is a strong advocate of the strategic linking of clinical and basic research, and is the founder and president of Perinet Inc., a biomedical development company created to facilitate the development of his laboratory's findings. His research collaborations are worldwide.
Clinically, Dr. Weiner was one of the early practitioners of fetal medicine, focusing on the application of human fetal physiology to clinical practice. He was one of the first in North America to perform ultrasound directed fetal blood sampling and transfusion. He and his colleagues in the Center for Advanced Fetal Care have contributed to the modern management of fetal alloimmune disease, the role of fetal viral infection in adverse fetal outcome, and the application of fetal Doppler velocimetry in sequential vascular beds to fetal surveillance and diagnosis.
Dr. Weiner's enthusiasm for the application of physiology to medicine and the importance of translational research is infectious. He has mentored more than a dozen fellows from the U.S. and abroad in either fetal medicine or in his laboratory; all have gone on to receive independent extramural funding, and almost all remain in academic medicine. He has made more than 250 invited presentations throughout the world on his research interests.